TruthArchive.ai - Related Video Feed

Dr. Hotez explains that while vaccines are often described as miraculous, the development was not a four-month process but a seventeen-year effort dating back to the post-SARS period. After SARS emerged in 2003, researchers identified the spike protein as the virus’s soft underbelly and began experimental vaccine development. When the COVID-19 sequence was released in January, the coronavirus community quickly concluded that a vaccine could be made, and attention turned to which technology would be fastest and most enduring. All vaccines discussed (AstraZeneca, Pfizer, Moderna, J&J, and the one being scaled in India) target the spike protein. He emphasizes that this was a deliberate long-term program, not a rushed push. Nicole notes the broader context of vaccine safety, particularly on a day when a vaccine-skeptical witness testified before the Senate Homeland Security Committee. Dr. Hotez clarifies that the virus behind the current pandemic comes from a family of coronaviruses scientists have studied for a long time, and that once specifics emerged, researchers could finalize the vaccine approach. He reiterates the importance of reassurance about safety in light of public skepticism. Dr. Hotez highlights the role of the NIH and the National Institute of Allergy and Infectious Diseases, led by Tony Fauci, and Francis Collins at NIH, in launching a major coronavirus program beginning in 2003. This funding enabled the development of some of the first prototype vaccines, illustrating a deliberate US government and NIH investment to advance vaccine research. He notes the ongoing need to assess rollout and production robustness, as this technology is brand new, and additional vaccines will be necessary to vaccinate populations. Looking ahead, the conversation acknowledges that the United States will require four or five different vaccines to achieve broad vaccination coverage, rather than relying solely on the two mRNA vaccines. The UK has begun vaccinations, marking an initial step, with plans to scale in the United States in the coming days. The discussion underscores a long road ahead to ensure scalable production, distribution, and multiple vaccine options to meet demand.

Speaker cites a broad concern among experts: 'there are quite a few people.' He names 'Nick Bostroman' and 'Bencio, another Turing Award winner who's also super concerned.' He cites 'a letter signed by, I think, 12,000 scientists, computer scientists saying this is as dangerous as nuclear weapons.' The discussion frames the topic as advanced technology: 'This is a state of the art.' 'Nobody thinks that it's zero danger.' There is 'diversity in opinion, how bad it's gonna get, but it's a very dangerous technology.' The speaker argues that 'We don't have guaranteed safety in place.' and concludes, 'It would make sense for everyone to slow down.'

I recently experienced a situation where a paper was reviewed by a high-profile journal, and a reviewer requested a BSL-three experiment without the author's knowledge. This highlights the pressure to publish at all costs, even if it means conducting risky experiments. I raised concerns with the journal editor, but it seemed they were unaware of the potential dangers. This incident serves as a warning about the dangers of prioritizing publication over safety. Be cautious of this trend.

Research on potential pandemic pathogens, known as gain of function studies, has led to valuable public health insights. Previous NSABB reports support this. While I won't argue for the necessity of this research, there are many freely available studies showing how mutations identified through these studies have helped us prepare for epidemics and pandemics.

The discussion centers on gain-of-function (GoF) research, its regulation, and the motivations behind it. The first speaker notes the administration’s goal to end GoF research and asks where that stands. The second speaker says progress has been made, and the White House is working on a formal policy. He then defines the issue in stages: what GoF research is, why someone would do it, and how to regulate it to prevent dangerous projects that could catastrophically harm human populations. He clarifies that GoF research is not inherently bad, but dangerous GoF research is. He gives an insulin example: creating bacteria to produce insulin is a legitimate GoF that benefits diabetics. In contrast, taking a virus from bat caves, bringing it to a lab in a densely populated city with weak biosafety, and manipulating it to be more transmissible among humans is a dangerous GoF that should not be supported. The administration’s policy aims to prevent such dangerous work entirely, and the President signed an executive order in April or May endorsing this policy. Next, he discusses implementation: how to create incentives to ensure this research does not recur. He explains that the utopian idea behind such research was to prevent all pandemics by collecting viruses from wild places, testing their potential to infect humans by increasing their pathogenicity, and then preparing countermeasures in advance (vaccines, antivirals) and stockpiling them, even though those countermeasures would not have been tested against humans yet. If a virus did leap to humans, the foreseen countermeasures might prove ineffective because evolution is unpredictable. This “triage” approach—identifying pathogens most likely to leap and preemptively preparing against them—was the rationale for dangerous GoF work, a rationale he characterizes as flawed. He notes that many scientists considered this an effort to do bioweapons research under the guise of safety and defense. The work is dual-use. The U.S. is a signatory to the Biological Weapons Convention and does not conduct offensive bio-weapons research, but other countries might. The discussion highlights that the GoF research discussed during the pandemic can backfire and may not align with true biodefense, since countermeasures might not match whatever pathogen actually emerges. The speaker concludes that this agenda—pursuing GoF to prevent pandemics—has drawn substantial support from parts of the Western world and other countries for about two and a half decades, but he implies it is not deserving of continuation.

The perception, not reality, leads to the killing of bio-threat defense projects. 50% of allies believe the US has an offensive bioweapons program, which is false. Since Nixon, there has been no such program. Developing countermeasures against bio-threats can be mistaken for an offensive program, causing public and political concerns. The information will be published in Science and Nature soon.

The symposium covers the potential safety and threat of “replicating” vaccines, especially LepriCon (leprecon) vaccines, in the context of Covid-19 vaccines and genome‑editing concepts. The speakers present a chain of claims and concerns, some drawing on reports and others presenting theories about how these next‑generation vaccines could behave in humans and populations. Key points and claims presented - Emerging mechanisms and risks: The panel notes that blood vessel inflammation and thrombosis mechanisms are increasingly observed, including in vaccine contexts, with examples from individuals who needed limb amputation and others who developed severe vascular events after vaccination. One case involved a 70‑year‑old man who, after a third dose, developed embolic events necessitating shoulder joint surgery, and another where a 60‑year‑old man developed acute limb ischemia and died; both are presented as suggesting a serious vascular mechanism linked to vaccination, though causal connections are not established. - Replicating/vector vaccines and their concerns:荒川博士 and others discuss LepiCon vaccines as vaccines that replicate inside the body. The concept involves “replicating viral vectors” where the genome can mutate and evolve during replication. The green‑highlighted segment in a slide (the antigen gene) plus a blue/orange segment (replicating gene cassette) is used to describe how LepriCon vaccines are designed to carry viral genes and replicate, with the assertion that replication, mutation, and recombination can occur, potentially generating new variants inside the host. - Differences from conventional vaccines: The discussion contrasts LepriCon vaccines with standard mRNA vaccines. In conventional mRNA vaccines, messenger RNA is delivered and translated into antigen proteins, then degraded; in LepriCon vaccines, replicating RNA/DNA can persist and continue producing antigen, with mutation and recombination possible. The panel emphasizes that LepriCon vaccines use replicating/copying mechanisms and that the genetic material can be copied in ways that differ from natural human biology, potentially creating unpredictable variants. - Central dogma and exceptions: The speakers reference the central dogma (DNA → RNA → protein) but note exceptions in viruses, including RNA viruses that can reverse‑transcribe to DNA (retroviruses) and RNA viruses that replicate RNA directly. They discuss how LepriCon vaccines would rely on replicative processes that do not follow the usual linear flow and why this could complicate predictions about safety and behavior in humans. - Potential for unintended spread and environmental impact: A major concern raised is that self‑replicating vectors could spread beyond the vaccinated individual, via exosomes or other intercellular transport, creating secondary infections or non‑target spread. Exosomes could ferry replicating genetic material, raising fears of new infection chains or “outbreaks” stemming from the vaccine itself, and even suggesting the possibility of vaccination‑induced spread akin to an attenuated or modified pathogen. - Safety signals and immunology concerns: The discussion touches on immune system risks, including immune dysregulation, autoimmune phenomena, and unexpected inflammatory responses. IGG4‑related disease is highlighted as a potential adverse outcome post‑vaccination, with descriptions of glandular and systemic involvement and the idea that high IGG4 levels could have immunosuppressive effects that alter responses to infection or vaccination. The panel notes observed increases in certain immunoglobulin subclasses after multiple LepriCon doses and discusses the possibility of immune tolerance or enhanced immune responses that could be harmful. - Historical and theoretical context: References are made to past epidemics and speculative pandemics caused by misused or dangerous vaccine platforms, drawing on central molecular biology concepts and historical anecdotes about how vaccines can be designed and misused. The discussion frames LepriCon vaccines as a high‑risk platform that could, in theory, generate recombinants, escape mutations, or cause unintended immune and inflammatory consequences. - Clinical and regulatory implications: The speakers call for caution, arguing that more evidence is needed before approving or widespread use of LepriCon vaccines. They emphasize the need for long‑term observation and transparent communication about risks, and criticize the potential for insufficient understanding among healthcare workers and the public. They also urge that any future vaccine development should consider the possibility of genome editing, recombination, and exosome‑mediated spread, and stress the importance of not underestimating possible adverse effects. - Real‑world observations and skepticism about hype: Several speakers underscore that the danger is not merely hypothetical; there are reports of adverse events, including stroke‑like conditions, inflammatory diseases, and immune dysregulation in vaccinated individuals. They stress that the evolution and mutation of replicating vaccines could outpace current surveillance methods, and that “information manipulation” or lack of transparent reporting could mislead the public about risks. - Final reflections and call to action: The concluding messages advocate recognizing the potential failures of messenger RNA vaccines and acknowledging that both conventional and replicating platforms may carry risks. The speakers urge ongoing critical analysis, cautious progression, and robust verification of claims through transparent, independent investigation. They close with thanks to the organizers and a hope that the discussion may contribute to broader public awareness and informed decision‑making. Notable emphasis and unique considerations - The core concern centers on LepriCon vaccines’ replication, mutation, and potential to spread beyond the vaccinated person; exosome transport and genomic/cellular integration are highlighted as mechanisms that could generate new risks not present with non‑replicating vaccines. - The discussion stresses that IGG4 responses could become alarmingly high after certain doses, potentially leading to immunosuppressive effects or autoimmune phenomena, and presents IGG4‑related disease as a potential complication to monitor. - The speakers insist that safety and transparency are paramount, and that misinformation or optimistic narratives about rapid vaccine development could lead to harm if new platforms are adopted without comprehensive evaluation. Overall, the symposium foregrounds cautious scrutiny of replicating vaccine platforms, frames potential biological and regulatory risks, and calls for careful, evidence‑based assessment before broader deployment.

There was a recent FDA rejection of an MDMA-based therapy for PTSD, a program that had achieved, on its own terms, two successful phase three studies. The speaker notes that the trials were designed exactly as the FDA told them to design, but the episode is tied to the rise of advisory committees—FDA panels of so-called experts who opine on data and recommendations. The FDA is not bound by their recommendations, but they often follow them, sometimes not. In the speaker’s view, the FDA uses these advisory committees as a cover for what they actually want to do, a dynamic the speaker has observed across years in biotech as an investor and company builder. He has sat in eight-hour advisory committee sessions in Maryland, taking detailed notes, and while he didn’t attend the most recent one, he believes it smelled like the briefing documents provided to the committee were used to guide the outcome. He suspects the advisory committee recommended against approval, and the FDA then moved to that outcome. The speaker argues this is a travesty for PTSD patients who have very few options. He focuses on the reasoning the FDA gave for denying approval: the trial was functionally unblinded. Typically, trials use placebo and active drug arms with participants unaware of which treatment they receive, to ensure that observed effects are not merely placebo. The FDA claimed that patients knew whether they were on the MDMA-based therapy because some experienced euphoria, a side effect of the treatment. Therefore, the therapy could appear to work due to unblinding and a placebo effect, rather than a true therapeutic benefit. The speaker emphasizes that the possibility of euphoria being part of the drug’s mechanism—and thus related to its therapeutic effect—was ignored in their assessment, and that this unblinding was, in his view, anticipated by the FDA before agreeing to the phase three protocol, which also added tens or hundreds of millions of dollars in development costs. The speaker criticizes the public record, including biotech press coverage, for focusing on “trial irregularities” or an unblinding issue rather than on the broader cost-benefit and mechanistic considerations. He asserts that the public is left with the notion that there were unblinding issues, not recognizing that the unblinding related to the drug’s therapeutic properties was anticipated and approved by the FDA. He concludes that the episode reveals how the bureaucratic machinery operates, with advisory committees and briefing documents shaping outcomes in a way that aligns with the FDA’s underlying aims.

Many journal policies were created during a time of biosecurity focus, neglecting population-level biosafety concerns. Transparency in the approval process is important, with the public having a right to know. If openness leads to disapproval, it raises questions about why approval was granted in secret.

A birth cohort study on the impact of childhood vaccination on short- and long-term chronic health outcomes reports results from a large sample (18,468 subjects). The discussion surrounding the study emphasizes that, if results showed vaccines were associated with chronic diseases, the findings would be highly compelling and valuable. The reported outcomes from the vaccinated group include: - Asthma diagnosis: vaccinated subjects were over four times more likely to have an asthma diagnosis. - Acute and chronic ear infections: six hundred percent more. - Speech disorders: four point four seven times the amount in the vaccinated compared to the unvaccinated. - Learning issues and related developmental concerns: a six hundred and sixteen percent increase in learning issues, developmental delays, speech delays, and language delays. In contrast, the unvaccinated group is described as having zero occurrences in several categories, including dysfunction, diabetes, behavioral problems, learning disabilities, intellectual disabilities, tics, and other psychological disabilities. The discussion highlights the magnitude of the differences as a major point of emphasis, with statements such as “It’s a big difference” and “This is devastating.” There is strong advocacy for the study’s publication, including claims that “This paper should have been rushed to publication on an emergency basis.” The speakers assert, “We are systematically making kids sick and not just a little bit sick, very sick.” They describe the study as potentially “the most important study that has ever been done,” insisting that it needs to be published, and noting that if a particular researcher “puts his name on this, his career is over.” Emotional reactions are evident, with admissions like “I mean, obviously, like, really emotional.” There is a specific mention that “Zervos probably gonna lose his job over this.”

The speakers discuss the framing of risk and benefit in scientific research, emphasizing the need for more clarity in defining these terms. They also touch on the issue of self-censorship among scientists due to funding uncertainties. The conversation highlights the importance of foundational research despite potential lack of immediate benefits. Additionally, they address the need for more transparency in discussions surrounding risk and benefit in research proposals.

The speaker argues that an irrational, unbridled enthusiasm for new possibilities leads to a sacrifice of safety. This enthusiasm, in their view, has adversely affected precautionary considerations and risk assessment. They reference presenting autopsy findings related to deaths following COVID-19 vaccination at the American Society of Microbiology, an event attended by thousands of microbiologists, vaccinologists, and immunologists. In conversations with attendees, the speaker was surprised by what they describe as a scientific seduction surrounding messenger RNA technology. The core concern expressed is that this eagerness to embrace mRNA platforms is accompanied by a neglect of safety considerations. The speaker asserts that there will be a cataclysmic recognition that messenger RNA technology represents an unsafe platform. They emphasize that, as they understand it, there is no way to break down certain aspects of the technology they refer to as “pseudourogenated messenger RNA,” noting this within the context of their work in research laboratories. The statement implies a belief that the degradation or metabolic processing of this form of RNA poses unresolved issues. A central, striking claim presented is that circulating messenger RNA from Pfizer or Moderna has been found in their patients’ bloodstream three years after vaccination, and that this RNA is intact. The speaker underscores this as evidence tied to their observations and research experiences, asserting the persistence of the RNA in the circulatory system over an extended period. Overall, the message conveys a perspective that rapid adoption and optimism around mRNA vaccines and technologies have overshadowed safety considerations, and it anticipates a future realization of safety concerns associated with these platforms. The speaker ties their warnings to concrete experiences at a major scientific conference and to specific, long-term biomarkers observed in patients, presenting a narrative of ongoing research findings and anticipated paradigm shifts in how the safety of mRNA vaccines is perceived.

The panel discusses replication (replicon) vaccines and their potential dangers, focusing on how they differ from conventional messenger RNA (mRNA) vaccines and what new risks might emerge as this technology develops. Key points and concerns raised - Replicon vaccines concept and fundamental differences - Replicon vaccines use replication-capable genetic material, so the embedded genetic information not only makes antigen proteins but also multiplies inside the cell. They are described as having both constitutive function (the ability to make proteins) and, crucially, the capacity to replicate, which distinguishes them from traditional, non-replicating mRNA vaccines. - It is explained that replication introduces additional mutation and recombination opportunities, because the RNA genome is copied more than once, and the process can produce variants that differ from the original design. - Central dogma exceptions and viral biology - The speakers explain that while the central dogma (DNA → RNA → protein) generally governs biology, some viruses violate this, with RNA viruses that replicate via RNA-dependent replication and even some reverse-transcribing retroviruses that convert RNA to DNA and integrate into genomes. This context is used to frame why replicon vaccines could behave unpredictably. - Potential risks of replication and spread - A core concern is that the replicon approach might allow the vaccine genome to spread beyond the initial target cells, potentially reaching other cells and tissues, or even spreading to other people via exosomes or other means. Exosomes can transport DNA, RNA, and proteins between cells; thus, the replicon genome could in theory be disseminated. - The possibility of homologous or heterologous recombination between replicon genomes and wild-type viruses could yield new variants. The panel emphasizes the difficulty of controlling such recombination in a living system. - Specific material and design considerations - The use of viral components like spike protein genes in replicon vaccines raises concerns about how these proteins might mutate or recombine during replication, potentially altering antigen presentation or safety. - A concern is raised about the lack of repair mechanisms in RNA replication (as opposed to DNA replication), which could make error rates higher and lead to unpredictable changes. - The panel notes that current replicon vaccine designs (including those using alphavirus backbones) inherently carry high mutation and recombination risk, and that the replicating systems may encounter unpredictable evolutionary dynamics inside the human body. - Safety signals and clinical anecdotes - The speakers cite cases of adverse events temporally associated with vaccines, including vascular inflammation and thrombosis, stroke-like events, and myocarditis, to illustrate that immune responses to vaccines can be complex and occasionally severe. They emphasize that such observations do not establish causality, but argue they warrant careful scrutiny. - There are references to cases of acute vascular and neural complications following repeated vaccination, and to broader immune dysregulation phenomena, including IGG4-related disease and immune dysregulation syndromes that can involve multiple organs. - One example concerns a patient who developed sudden limb problems after the third dose, requiring surgery; another describes myocardial involvement after multiple doses and subsequent inflammatory sequelae. - DNA contamination and analytical findings - Kevin McKernan’s analysis of certain Japanese CoronaVac vaccines is cited: both DNA contamination and the presence of SV40 promoter elements were detected in some vaccine lots, with DNA amounts exceeding some regulatory benchmarks in at least one case. The concern is that DNA contamination, or the presence of promoter sequences, could influence integration or expression in unintended ways. - It is noted that vaccines using lipid nanoparticles can potentially deliver nucleic acids into cells; in the presence of exons or promoter sequences, there could be unintended cellular uptake and expression. - Implications for public health and policy - The panel underscores the need for caution, thorough investigation, and long-term observation of any replication-based vaccine platform before broad deployment. There is a call to evaluate risks, monitor long-term outcomes, and consider the possibility that replication-competent constructs could drive unforeseen evolutionary dynamics within hosts or communities. - There is contention about how information is communicated to the public, with particular emphasis on avoiding misinformation while ensuring that scientific uncertainties are transparently discussed. - Broader scientific context and forward-looking stance - The speakers discuss how the field’s approach to gene-based vaccines is evolving rapidly, and they stress that the compatibility of replicon systems with human biology is not yet fully understood. - They frame their discussion as not merely about current vaccines but about the trajectory of vaccine platforms: if replication-based or self-dispersing systems prove too risky or unpredictable, the prudent path might be to favor conventional, non-replicating strategies until safety, efficacy, and containment of unintended spread are more firmly established. Closing and takeaways - The session closes with emphasis on careful evaluation of replicon vaccines, awareness that viral genetics can behave differently in humans than in theory, and a call for continued discussion, independent verification, and transparent communication as the technology develops. - Throughout, speakers acknowledge the complexity of immune responses to vaccines, the potential for unexpected adverse events, and the importance of safeguarding public health while advancing vaccine science.

Speaker emphasizes 'no interference in research' and urges that 'this government or who or we, the people, stand up for, you know, righteous research and no retraction of data and no interference in research.' They argue that while the public may be educated by podcasts, 'doctors, the scientists are gonna be educated by watching by reading the data.' Addressing labeling, they state that 'mislabeling that that, the the labels that mislead the consumers, we're never gonna fix our micro I agree.' They reference Kennedy, saying 'Kennedy's saying it's propaganda. This research has been basically propaganda. And, now, hopefully, he's going to put an end to it, but it's a it's a long row.'

Some committee members were concerned about making the list too broad, fearing a difficult review process and unnecessary restrictions on research. Transparency was a key issue, with a desire for a transparent review process while maintaining some level of confidentiality. There were discussions about potential oversight by different organizations, but concerns were raised about the balance between transparency and secrecy. Maintaining transparency is important, but opinions on what constitutes transparency can vary.

Caution about long-term side effects of modifying people’s DNA and RNA to directly encode the ability to produce antibodies, and whether this could cause other mutations or downstream risks.

My understanding of the PC30 framework is that it focuses on a small number of viruses with both pathogenicity and transmissibility. However, there are discrepancies in the criteria used, leading to unintended studies being included. More refinement may be needed to ensure accurate submissions. The definition on paper may not always align with real-world practices.

On COVID, there's a perception that credit isn't given where it's due. While the vaccines were developed quickly, they don't prevent infection or transmission and may have serious side effects. In hindsight, would anything be done differently? Studies on the vaccines are ongoing, and results will emerge over time. It's important to note that Pfizer marketed its vaccine as safe for pregnant women, but reports indicated that over half of the 458 pregnant women who received the vaccine experienced adverse events. The ongoing studies will help clarify these concerns.